AngioDynamics, Inc.
NASDAQ:ANGOMedical - Instruments & Supplies
+$0.20 today
- Market cap
- $476.06M
- Beta
- 0.36
- P/E (TTM)
- -15.8
- EPS (TTM)
- -$0.75
Volume 0.32M
Average 0.40M
ANGO Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
AngioDynamics, Inc.NASDAQ: ANGO
Stock-Based Compensation · Q3 FY2026 · quarter ended Feb 2026
Stock-based compensation grows, but more slowly than its trailing trend
Q3 FY2026 stock-based compensation of $2.68M rose 11.9% year over year, behind the +16.5% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 7.2% from the prior quarter. Over 3 fiscal years it compounded at -3.0% a year.
Context
- Stock-based compensation amounted to 3.3% of revenue in FY2025, down 0.1 pp from a year earlier.
- Stock-based compensation increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +11.9% toward the trailing-twelve-month pace of +16.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 9.77M USD
- Year-over-year change
- -7.2%
- 4-year CAGR
- +3.2%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-05-31 | 9.77M | -7.2% |
| FY2024 | 2024-05-31 | 10.53M | -5.6% |
| FY2023 | 2023-05-31 | 11.16M | +4.4% |
| FY2022 | 2022-05-31 | 10.69M | +24.0% |
| FY2021 | 2021-05-31 | 8.63M | — |
Stock-Based Compensation vs competitors
How ANGO compares with its peers on the latest reported figures
- ANGO's LTM Feb 2026 stock-based compensation of $11.69M is the 8th largest of the 9 companies compared; the peer median is $33.64M.
- Its year-over-year change of +16.5% is the 2nd highest of 9, against a peer median of +5.6%.
- Stock-based compensation amounts to 3.7% of revenue for ANGO, versus a peer median of 1.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $204M | +270.9% | — | 1.0% | |
| LTM Jun 2026 | $166M | +5.7% | +10.8% | 0.8% | |
| LTM Jun 2026 | $59.5M | +16.5% | — | 4.0% | |
| LTM Sep 2026 | $45.39M | +5.4% | +34.1% | 2.8% | |
| LTM Mar 2026 | $21.88M | +6.0% | -12.5% | 1.3% | |
| LTM Jun 2026 | $20.21M | -33.5% | — | 0.8% | |
| LTM Mar 2026 | $19.96M | -39.8% | +9.2% | 1.5% | |
| LTM Feb 2026 | $11.69M | +16.5% | -3.0% | 3.7% | |
| LTM Mar 2026 | $5.78M | -17.5% | +23.3% | 2.3% | |
| Peer median (excluding ANGO) | $33.64M | +5.6% | +10.8% | 1.4% | |
Competitors are the stored peer set for ANGO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 May 2021 | FY2022 May 2022 | FY2023 May 2023 | FY2024 May 2024 | FY2025 May 2025 |
|---|---|---|---|---|---|
| Net Income | (31.55M) | (26.55M) | (52.44M) | (184.35M) | (33.99M) |
| Depreciation & Amortization | 25.92M | 29.35M | 30.87M | 27.71M | 25.8M |
| Deferred Income Tax | (4.81M) | (3.71M) | (2.31M) | (7.97M) | (988K) |
| Stock-Based Compensation | 8.63M | 10.69M | 11.16M | 10.53M | 9.77M |
| Change in Working Capital | 9.07M | (21.05M) | (7.03M) | 14.42M | (14.11M) |
| Accounts Receivables | (4.16M) | (17.15M) | (1.3M) | 7.89M | 23K |
| Inventory | 11.54M | (2.8M) | (8.2M) | (9.41M) | (1.35M) |
| Accounts Payables | 4.88M | 3.91M | 2.14M | 27.53M | (15.88M) |
| Other Working Capital | (3.18M) | (5.01M) | 332K | (11.59M) | 3.09M |
| Other Non-Cash Items | 16.83M | 4.07M | 19.83M | 111.5M | 3.39M |
| Operating Cash Flow | 24.09M | (7.19M) | 78K | (28.16M) | (10.13M) |
| Capital Expenditures | (5.19M) | (4.3M) | (4.35M) | (5.77M) | (4.46M) |
| Acquisitions (Net) | 0 | (3.6M) | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (8.52M) | (11.41M) | (5.93M) | 126.24M | (5.71M) |
| Investing Cash Flow | (13.71M) | (19.31M) | (9.75M) | 123.72M | (10.18M) |
| Debt Repayment | (20M) | 5M | 25M | (50M) | 6.16M |
| Common Stock Issued | 3.01M | 2.68M | 1.17M | 752K | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (1.67M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | (751K) | (15M) | (4.75M) |
| Financing Cash Flow | (16.99M) | 7.68M | 25.42M | (64.25M) | (255K) |
| Effect of Forex Changes | 330K | (518K) | 43K | 125K | 398K |
| Net Change in Cash | (6.27M) | (19.34M) | 15.8M | 31.44M | (20.16M) |
| Free Cash Flow | 18.91M | (11.49M) | (4.27M) | (33.93M) | (14.59M) |
AngioDynamics, Inc.
NASDAQ:ANGO
Intrinsic Alpha fair value
Locked
Current Price
$11.32
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.